Abstract
Vaccines are primarily employed for triggering the acquired immune response of the body to combat against diverse pathogenic organisms. Conventional approaches for vaccine delivery possess multiple challenges for effective delivery owing to lack of potential for targeting ability to a particular antigen and protection of antigens from physiological environments of body. In the past a few decades, nanocolloidal carriers have gained higher attention in vaccine delivery due to advantages of targeting ability, reduced immunogenicity and significant augmentation in immune response. Instances of colloidal carriers employed for vaccine delivery include liposomes, niosomes, microspheres, proteosomes, virosomes and virus like particles, reconstituted influenza viruses, immunostimulating complexes, antigen cochleates, etc. Further, surface engineering of these carriers with ligands, functional moieties and monoclonal antibodies has yielded enhanced immune recognition potential to the vaccine antigens for eliciting immune response by promoting differentiation of the antigen specific memory T-cells. In a nutshell, the present review provides an updated and exhaustive account on the recent advancements in various colloidal delivery systems employed for vaccine delivery outlining their potential applications, mechanism of augmenting the immune response and instances of the products existing in market in an explicit manner.
Keywords: Nanocarriers, vaccines, liposomes, IRIVs, niosomes, immune response.
Current Drug Therapy
Title:Novel Nanocolloidal Carriers for Noninvasive Vaccine Delivery
Volume: 9 Issue: 3
Author(s): Sarwar Beg, Mahfoozur Rahman, Suryakanta Swain and Syed Sarim Imam
Affiliation:
Keywords: Nanocarriers, vaccines, liposomes, IRIVs, niosomes, immune response.
Abstract: Vaccines are primarily employed for triggering the acquired immune response of the body to combat against diverse pathogenic organisms. Conventional approaches for vaccine delivery possess multiple challenges for effective delivery owing to lack of potential for targeting ability to a particular antigen and protection of antigens from physiological environments of body. In the past a few decades, nanocolloidal carriers have gained higher attention in vaccine delivery due to advantages of targeting ability, reduced immunogenicity and significant augmentation in immune response. Instances of colloidal carriers employed for vaccine delivery include liposomes, niosomes, microspheres, proteosomes, virosomes and virus like particles, reconstituted influenza viruses, immunostimulating complexes, antigen cochleates, etc. Further, surface engineering of these carriers with ligands, functional moieties and monoclonal antibodies has yielded enhanced immune recognition potential to the vaccine antigens for eliciting immune response by promoting differentiation of the antigen specific memory T-cells. In a nutshell, the present review provides an updated and exhaustive account on the recent advancements in various colloidal delivery systems employed for vaccine delivery outlining their potential applications, mechanism of augmenting the immune response and instances of the products existing in market in an explicit manner.
Export Options
About this article
Cite this article as:
Beg Sarwar, Rahman Mahfoozur, Swain Suryakanta and Imam Sarim Syed, Novel Nanocolloidal Carriers for Noninvasive Vaccine Delivery, Current Drug Therapy 2014; 9 (3) . https://dx.doi.org/10.2174/1574885509666141202233804
DOI https://dx.doi.org/10.2174/1574885509666141202233804 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
Call for Papers in Thematic Issues
Novel Therapeutic Approaches and Biomarkers for Chronic Kidney Disease (CKD)
The thematic issue on "Novel Therapeutic Approaches and Biomarkers for CKD" aims to provide a comprehensive exploration of cutting-edge strategies for the management of chronic kidney disease (CKD). This issue will delve into emerging therapeutic targets, focusing on critical aspects such as podocyte injury, endothelial dysfunction, and tubulointerstitial fibrosis, which ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
From French Paradox to Cancer Treatment: Anti-cancer Activities and Mechanisms of Resveratrol
Anti-Cancer Agents in Medicinal Chemistry Tracking Cell Signaling Protein Expression and Phosphorylation by Innovative Proteomic Solutions
Current Pharmaceutical Biotechnology Small Molecule Toxins Targeting Tumor Receptors
Current Pharmaceutical Design Bioactive Components and Pharmacological Action of Wikstroemia indica (L.) C. A. Mey and Its Clinical Application
Current Pharmaceutical Biotechnology Tumour-Derived Glutamate: Linking Aberrant Cancer Cell Metabolism to Peripheral Sensory Pain Pathways
Current Neuropharmacology From HPV Infection to Oncogenesis: A Brief Review of the Complex Immunobiological Events
Current Cancer Therapy Reviews Viral Origins of Human Cancer
Current Medicinal Chemistry Recent Advances in Research on the Most Novel Carbonic Anhydrases,CA XIII and XV
Current Pharmaceutical Design The Role of NF-κB Inhibitors in Cell Response to Radiation
Current Medicinal Chemistry Design of Combretastatin A-4 Analogs as Tubulin Targeted Vascular Disrupting Agent with Special Emphasis on Their Cis-Restricted Isomers
Current Pharmaceutical Design Use of Naturally Occurring Peptides for Neuropathic Spinal Cord Injury Pain
Current Protein & Peptide Science Pharmaceutical and Biomedical Potential of PEGylated Dendrimers
Current Pharmaceutical Design A Dual Mode Pulsed Electro-Magnetic Cell Stimulator Produces Acceleration of Myogenic Differentiation
Recent Patents on Biotechnology Immunotherapeutic Approaches in MS: Update on Pathophysiology and Emerging Agents or Strategies 2006
Endocrine, Metabolic & Immune Disorders - Drug Targets Linezolid Activity Against Disseminated Listeria monocytogenes Meningitis and Central Nervous System Abscesses: Focus on Early Drug Myelotoxicity
Current Drug Safety Near-Infrared Quantum Dot Contrast Agents for Fluorescence Tissue Imaging: A Phantom Study
Current Nanoscience Strategy of Cancer Targeting Gene-Viro-Therapy (CTGVT) a Trend in Both Cancer Gene Therapy and Cancer Virotherapy
Current Pharmaceutical Biotechnology Overcoming Chemotherapy Resistance in High Grade Serous Ovarian Cancer
Current Cancer Therapy Reviews Adeno-Associated Virus Vectors: Immunobiology and Potential Use for Immune Modulation
Current Gene Therapy Regulation of Female Fertility and Identification of Future Contraceptive Targets
Current Pharmaceutical Design